Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 401 to 450 of 797

TitleReference numberPublishedLast updated
Sotagliflozin with insulin for treating type 1 diabetesTA622
Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal)TA618
Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedureTA617
Cannabidiol with clobazam for treating seizures associated with Dravet syndromeTA614
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndromeTA615
Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumabTA612
Pentosan polysulfate sodium for treating bladder pain syndromeTA610
Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia (terminated appraisal)TA608
Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal)TA609
Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery diseaseTA607
Lanadelumab for preventing recurrent attacks of hereditary angioedemaTA606
Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoeaTA605
Idelalisib for treating refractory follicular lymphomaTA604
Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal)TA603
Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA602
Benralizumab for treating severe eosinophilic asthmaTA565
Risankizumab for treating moderate to severe plaque psoriasisTA596
Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal)TA594
Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancerTA595
Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitisTA590
Letermovir for preventing cytomegalovirus disease after a stem cell transplantTA591
Nusinersen for treating spinal muscular atrophyTA588
Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activityTA589
Bisphosphonates for treating osteoporosisTA464
Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormalityTA322
Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapiesTA171
Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomibTA586
Lenalidomide plus dexamethasone for previously untreated multiple myelomaTA587
Ocrelizumab for treating primary progressive multiple sclerosisTA585
Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetesTA583
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancerTA584
Enzalutamide for hormone-relapsed non-metastatic prostate cancerTA580
Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphomaTA577
Certolizumab pegol for treating moderate to severe plaque psoriasisTA574
Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal)TA576
Tildrakizumab for treating moderate to severe plaque psoriasisTA575
Ertugliflozin as monotherapy or with metformin for treating type 2 diabetesTA572
Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinibTA571
Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal)TA570
Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancerTA569
Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal)TA568
Cochlear implants for children and adults with severe to profound deafnessTA566
Venetoclax with rituximab for previously treated chronic lymphocytic leukaemiaTA561
Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanomaTA562
Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancerTA563
Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal)TA560
Regorafenib for previously treated advanced hepatocellular carcinomaTA555
Darvadstrocel for treating complex perianal fistulas in Crohn's diseaseTA556
Lenvatinib for untreated advanced hepatocellular carcinomaTA551
Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemiaTA552

Results per page

  1. 10
  2. 25
  3. 50
  4. All